Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
India Globalization Capital, Inc. (IGC) has completed Cohort 2 of its Phase 1 clinical trial for IGC-AD1, a THC-based drug aimed at alleviating Alzheimer’s symptoms. The trial, approved by the FDA in July 2020, included an increase in dosage from one to two doses per day. The Data and Safety Monitoring Committee has recommended advancing to Cohort 3, where participants will receive three doses daily. The trial aims to assess safety and behavioral changes, concluding between July and September 2021, with potential future trials for efficacy depending on results.
India Globalization Capital (NYSE American: IGC) announced receiving patent #10,933,082 from the USPTO on March 2, 2021. This patent covers a cannabinoid composition and method for treating pain associated with Psoriatic Arthritis, Fibromyalgia, Scleroderma, and other conditions. The application was submitted on October 1, 2018. This approval enhances IGC's existing patent portfolio, which already includes patents for seizure and eating disorders.
India Globalization Capital (IGC) has initiated its phase 1 clinical trial for IGC-AD1, a THC-based investigational drug for Alzheimer's disease, approved by the FDA on July 30, 2020. The first dosing level has been administered to five of twelve patients, with ongoing enrollment. The trial aims to assess pharmacokinetics of THC and its interaction with the CYP2C9 gene, which is crucial for metabolizing THC and various medications. CEO Ram Mukunda highlighted that while no cure for Alzheimer's exists, THC may improve patient quality of life.
India Globalization Capital (IGC) reported financial results for Q3 2021, revealing a significant revenue decline to $108 thousand from $573 thousand in Q3 2020, primarily due to COVID-19 restrictions. Revenue was 15% from infrastructure and 85% from Life Sciences. The company faced increased expenses, with SG&A rising 55% to $2,186 thousand, largely driven by overheads, marketing, and a SEC settlement. The net comprehensive loss for the quarter was $2,283 thousand or $0.06 per share, compared to $1,646 thousand or $0.04 per share from the prior year.
India Globalization Capital (NYSE AMERICAN: IGC) held its Annual Meeting of Shareholders on January 11, 2021, where all voting matters disclosed in the Definitive Proxy were approved. Key outcomes included the election of John E. Lynch to the Board of Directors, ratification of Manohar Chowdhry & Associates as auditors for FY 2021, and approval to grant up to 2,500,000 shares to employees and advisors based on performance metrics. Additionally, the frequency of 'say-on-pay' votes was set to every three years.
India Globalization Capital, Inc. (NYSE American: IGC) announced the nomination of John E. Lynch as a Class A independent director, replacing Sudhakar Shenoy, at the upcoming 2020 Annual Meeting of Stockholders on January 11, 2021. Lynch, an intellectual property attorney, has been instrumental in IGC's patent strategy, helping to negotiate key patents, including those relevant to the therapeutic use of THC for Alzheimer’s. Additionally, he has served as an advisor to IGC for five years and has a strong academic background in law and chemistry.